(PRESS RELEASE) STOCKHOLM, 13-Mar-2019 — /EuropaWire/ — Summa Equity’s acquisition of Olink AB has been supported by EQT Credit through its Mid-Market Credit investment strategy. EQT Credit has provided a senior secured financing in support of the deal. Olink Proteomics … Read the full press release
Posted in Business, Financial, Investment, News, Pharma & Biotech, Sweden
Tagged acquisition, Alexandre Hökfelt, alternative funding, biology, biomarkers, EQT Credit, EQT Mid-Market Credit II, EQT Partners, human protein biomarker research, Olink, Paul Johnson, precision proteomics, private equity, protein biomarker discovery, protein biomarkers, Proximity Extension Assay, refinancings, Summa Equity, unitranche financing, Uppsala
STOCKHOLM, 04-Jun-2018 — /EuropaWire/ — EQT Credit, through its Mid-Market investment strategy, is pleased to announce that it has provided the financing to support Keensight Capital and ERES’ (the “Shareholders”) investment in Biovian (or the “Company”), a leading European player in … Read the full press release
Posted in Financial, Finland, Investment, Pharma & Biotech, Sweden
Tagged acquisition, biopharmaceuticals, Biovian, EQT Credit, ERES, financing, investment, Keensight Capital, Paul Johnson
STOCKHOLM, 19-Jan-2018 — /EuropaWire/ — EQT Credit, through its Mid-Market Credit investment strategy, today announces that it has provided EUR 115 million of financing to support Inspired’s (the “Company”) acquisition strategy. Inspired is a leading global operator of over 30 premium … Read the full press release
Posted in Education, Financial, Investment, Sweden
Tagged acquisition, Education, educators, EQT Credit, Inspired, K12, Nadim M. Nsouli, Paul Johnson, school
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
